DK1044015T3 - Formuleringer med amylinagonistpeptider og insulin - Google Patents

Formuleringer med amylinagonistpeptider og insulin

Info

Publication number
DK1044015T3
DK1044015T3 DK98902423T DK98902423T DK1044015T3 DK 1044015 T3 DK1044015 T3 DK 1044015T3 DK 98902423 T DK98902423 T DK 98902423T DK 98902423 T DK98902423 T DK 98902423T DK 1044015 T3 DK1044015 T3 DK 1044015T3
Authority
DK
Denmark
Prior art keywords
approximately
formulations
insulin
amylin agonist
agonist peptides
Prior art date
Application number
DK98902423T
Other languages
English (en)
Inventor
Italian James L
Shankar Musunuri
Cale Ruby
Original Assignee
Amylin Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amylin Pharmaceuticals Inc filed Critical Amylin Pharmaceuticals Inc
Application granted granted Critical
Publication of DK1044015T3 publication Critical patent/DK1044015T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
DK98902423T 1998-01-09 1998-01-09 Formuleringer med amylinagonistpeptider og insulin DK1044015T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US1998/000288 WO1999034822A1 (en) 1998-01-09 1998-01-09 Formulations for amylin agonist peptides

Publications (1)

Publication Number Publication Date
DK1044015T3 true DK1044015T3 (da) 2008-12-08

Family

ID=22266167

Family Applications (1)

Application Number Title Priority Date Filing Date
DK98902423T DK1044015T3 (da) 1998-01-09 1998-01-09 Formuleringer med amylinagonistpeptider og insulin

Country Status (9)

Country Link
EP (1) EP1044015B1 (da)
JP (1) JP4353544B2 (da)
AT (1) ATE410182T1 (da)
AU (1) AU760609B2 (da)
CA (1) CA2365742C (da)
DE (1) DE69840106D1 (da)
DK (1) DK1044015T3 (da)
ES (1) ES2316161T3 (da)
WO (1) WO1999034822A1 (da)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE417622T1 (de) 1996-08-08 2009-01-15 Amylin Pharmaceuticals Inc Regulation gastrointestinaler beweglichkeit
US5783556A (en) * 1996-08-13 1998-07-21 Genentech, Inc. Formulated insulin-containing composition
US7312196B2 (en) * 1997-01-08 2007-12-25 Amylin Pharmaceuticals, Inc. Formulations for amylin agonist peptides
JP4647736B2 (ja) * 1999-09-30 2011-03-09 小林製薬株式会社 薬剤発散具
EP2036539A1 (en) 2007-09-11 2009-03-18 Novo Nordisk A/S Stable formulations of amylin and its analogues
CN101822822A (zh) * 2009-03-04 2010-09-08 北京德众万全药物技术开发有限公司 一种普兰林肽的药物组合物及其制备方法
JP2009149684A (ja) * 2009-03-11 2009-07-09 Amylin Pharmaceut Inc アミリン作動薬ペプチド用製剤
CN102145164B (zh) * 2010-12-16 2013-02-27 深圳市健元医药科技有限公司 一种更加稳定的iapp类似物注射剂
US9399065B2 (en) 2012-04-16 2016-07-26 Biodel Inc. Magnesium compositions for modulating the pharmacokinetics and injection site pain of insulin
UA116217C2 (uk) 2012-10-09 2018-02-26 Санофі Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
JP2016503771A (ja) 2012-12-21 2016-02-08 サノフイ エキセンジン−４誘導体
EP3080150B1 (en) 2013-12-13 2018-08-01 Sanofi Exendin-4 peptide analogues as dual glp-1/gip receptor agonists
EP3080154B1 (en) 2013-12-13 2018-02-07 Sanofi Dual glp-1/gip receptor agonists
WO2015086730A1 (en) 2013-12-13 2015-06-18 Sanofi Non-acylated exendin-4 peptide analogues
EP3080149A1 (en) 2013-12-13 2016-10-19 Sanofi Dual glp-1/glucagon receptor agonists
TW201625670A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑
TW201625668A (zh) 2014-04-07 2016-07-16 賽諾菲公司 作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物
TW201625669A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑
CA2947587C (en) 2014-05-02 2022-10-18 The Research Foundation For The State University Of New York Islet amyloid polypeptides with improved solubility
US9932381B2 (en) 2014-06-18 2018-04-03 Sanofi Exendin-4 derivatives as selective glucagon receptor agonists
AR105319A1 (es) 2015-06-05 2017-09-27 Sanofi Sa Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
AR105284A1 (es) 2015-07-10 2017-09-20 Sanofi Sa Derivados de exendina-4 como agonistas peptídicos duales específicos de los receptores de glp-1 / glucagón
CN107952064B (zh) * 2016-10-14 2023-10-20 江苏豪森药业集团有限公司 含有聚乙二醇洛塞那肽的药物制剂及其制备方法
WO2018122278A1 (fr) * 2016-12-27 2018-07-05 Adocia Compositions sous forme de solution aqueuse injectable comprenant de l'amyline, un agoniste au récepteur de l'amyline ou un analogue d'amyline et un co-polyaminoacide
WO2018144671A1 (en) 2017-02-01 2018-08-09 The Research Foundation For The State University Of New York Mutant islet amyloid polypeptides with improved solubility and methods for using the same
WO2019038412A1 (en) 2017-08-24 2019-02-28 Novo Nordisk A/S GLP-1 COMPOSITIONS AND USES THEREOF
US11110063B2 (en) 2017-08-25 2021-09-07 MAIA Pharmaceuticals, Inc. Storage stable sincalide formulations
AU2021207313A1 (en) 2020-02-18 2022-07-28 Novo Nordisk A/S Pharmaceutical formulations

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4654324A (en) * 1981-08-27 1987-03-31 Eli Lilly And Company Human proinsulin pharmaceutical formulations
US5321008A (en) * 1991-01-10 1994-06-14 Amylin Pharmaceuticals, Inc. Methods and compositions for treatment of diabetes mellitus, hypoglycemia, and other conditions
ATE205854T1 (de) * 1991-11-19 2001-10-15 Amylin Pharmaceuticals Inc Peptide als amylin-agonisten und ihre verwendung
US6143718A (en) * 1995-06-07 2000-11-07 Amylin Pharmaceuticals, Inc. Treatment of Type II diabetes mellutis with amylin agonists
US7910548B2 (en) * 1997-06-06 2011-03-22 Amylin Pharmaceuticals, Inc. Methods for treating obesity

Also Published As

Publication number Publication date
EP1044015A4 (en) 2001-05-23
CA2365742A1 (en) 1999-07-15
CA2365742C (en) 2013-04-30
DE69840106D1 (de) 2008-11-20
AU760609B2 (en) 2003-05-15
EP1044015B1 (en) 2008-10-08
JP4353544B2 (ja) 2009-10-28
WO1999034822A1 (en) 1999-07-15
ES2316161T3 (es) 2009-04-01
JP2002511103A (ja) 2002-04-09
ATE410182T1 (de) 2008-10-15
EP1044015A1 (en) 2000-10-18
AU5909498A (en) 1999-07-26

Similar Documents

Publication Publication Date Title
DK1044015T3 (da) Formuleringer med amylinagonistpeptider og insulin
ES2569949T3 (es) Formulaciones farmacéuticas que comprenden un péptido complejado con una dicetopiperazina
US5766582A (en) Stable, aqueous alfa interferon solution formulations
HU202761B (en) Process for producing stabilized erythropoietin compositions
CA2295140A1 (en) Stable insulin formulations
EP2586459B1 (en) Vegf antagonist formulations
JPH0430926B2 (da)
WO2003101395A3 (en) Formulations for amylin agonist peptides
EA004761B1 (ru) Стабилизированная жидкая композиция паратиреоидного гормона, флакон с композицией и способы их получения
DE59908745D1 (de) Pharmazeutische ciclosporin-formulierung mit verbesserten biopharmazeutischen eigenschaften, erhöhter physikalischer qualität & stabilität sowie verfahren zur herstellung
ES2089011T3 (es) Excipiente lipidico de administracion nasal y aplicacion topica.
JP3927248B2 (ja) Ｈｇｆ凍結乾燥製剤
JP2009091363A (ja) Ｐｔｈの安定化水溶液注射剤
AR040529A1 (es) Formulaciones de hgh en alta concentracion que contienen 1,2-propilenglicol
ATE228005T1 (de) Pharmazeutische formulierungen aus corticotropin freisetzenden faktor mit verbesserter stabilitaet in fluessiger form
CN1802171B (zh) 不包含血清白蛋白的人红细胞生成素的稳定水溶液
JPH06247872A (ja) 高濃度ｔｃｆ製剤
US4963529A (en) Stable growth hormone releasing factor preparation
JP4252260B2 (ja) Ｐｔｈの安定化水溶液注射剤
Uebel et al. Stability evaluation of a prostaglandin E1 saline solution packed in insulin syringes
JPH1149698A (ja) 安定性を向上させたラクトフェリンの水性製剤
AHMAD et al. Stability of chlorpheniramine maleate in cough syrups
JP2003300908A (ja) 安定なカルシトニン注射用製剤
JPH10298102A (ja) カルシトニン注射液
JPH10287569A (ja) アシクロビル又はその塩の輸液型キット注射剤